Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications

Numerous models have been developed to quantify the combined effect of various risk factors to predict either risk of developing breast cancer, risk of carrying a high-risk germline genetic mutation, specifically in the BRCA1 and BRCA2 genes, or the risk of both. These breast cancer risk models can be separated into those that utilize mainly hormonal and environmental factors and those that focus more on hereditary risk. Given the wide range of models from which to choose, understanding what each model predicts, the populations for which each is best suited to provide risk estimations, the current validation and comparative studies that have been performed for each model, and how to apply them practically is important for clinicians and researchers seeking to utilize risk models in their practice. This review provides a comprehensive guide for those seeking to understand and apply breast cancer risk models by summarizing the majority of existing breast cancer risk prediction models including the risk factors they incorporate, the basic methodology in their development, the information each provides, their strengths and limitations, relevant validation studies, and how to access each for clinical or investigative purposes.

[1]  W. E. Hoogendoorn,et al.  Modeling familial clustered breast cancer using published data. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[2]  Adriano Decarli,et al.  Risk factor modification and projections of absolute breast cancer risk. , 2011, Journal of the National Cancer Institute.

[3]  L. Richardson,et al.  Diagnostic Accuracy of the Gail Model in the Black Women’s Health Study , 2007, The breast journal.

[4]  Barry I Graubard,et al.  The risk of developing invasive breast cancer in Hispanic women , 2013, Cancer.

[5]  N. Carson,et al.  A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center , 2000, Clinical genetics.

[6]  A. LaCroix,et al.  Evaluating breast cancer risk projections for Hispanic women , 2012, Breast Cancer Research and Treatment.

[7]  M. Shoukier,et al.  Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families , 2011, Familial Cancer.

[8]  J. Hopper,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions , 2008, British Journal of Cancer.

[9]  Z. Shao,et al.  Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients , 2009, Breast Cancer Research and Treatment.

[10]  Ammarin Thakkinstian,et al.  Risk prediction models of breast cancer: a systematic review of model performances , 2012, Breast Cancer Research and Treatment.

[11]  Kee Seng Chia,et al.  Validation of the Gail model for predicting individual breast cancer risk in a prospective nationwide study of 28,104 Singapore women , 2012, Breast Cancer Research.

[12]  N E Day,et al.  A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes , 2002, British Journal of Cancer.

[13]  D. Easton,et al.  BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families , 2005, Breast Cancer Research.

[14]  D. Euhus Understanding Mathematical Models for Breast Cancer Risk Assessment and Counseling , 2001, The breast journal.

[15]  N. Obuchowski,et al.  Assessing the Performance of Prediction Models: A Framework for Traditional and Novel Measures , 2010, Epidemiology.

[16]  N Risch,et al.  Genetic analysis of breast cancer in the cancer and steroid hormone study. , 1991, American journal of human genetics.

[17]  A. Lemke,et al.  Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population , 2009, Genetics in Medicine.

[18]  D. West,et al.  Accuracy of BRCA1/2 Mutation Prediction Models for Different Ethnicities and Genders: Experience in a Southern Chinese Cohort , 2012, World Journal of Surgery.

[19]  J. Benichou,et al.  Secular stability and reliability of measurements of the percentage of dense tissue on mammograms. , 2003, Cancer detection and prevention.

[20]  K Offit,et al.  BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. , 1997, JAMA.

[21]  G. Colditz,et al.  Validation of Rosner–Colditz breast cancer incidence model using an independent data set, the California Teachers Study , 2013, Breast Cancer Research and Treatment.

[22]  Rongwei Fu,et al.  Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: A Systematic Review to Update the U.S. Preventive Services Task Force Recommendation , 2014, Annals of Internal Medicine.

[23]  J. Oosterwijk,et al.  Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of ‘easy to apply’ probability models , 2006, British Journal of Cancer.

[24]  Giovanni Parmigiani,et al.  Simplifying clinical use of the genetic risk prediction model BRCAPRO , 2013, Breast Cancer Research and Treatment.

[25]  Anthony Howell,et al.  Breast cancer risk-assessment models , 2007, Breast Cancer Research.

[26]  J. Wolfe,et al.  Mammographic features and breast cancer risk: effects with time, age, and menopause status. , 1995, Journal of the National Cancer Institute.

[27]  D. Easton,et al.  BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface , 2013, British Journal of Cancer.

[28]  N F Boyd,et al.  Mammographic densities and breast cancer risk. , 1998, Breast disease.

[29]  Peter Kraft,et al.  Inclusion of endogenous hormone levels in risk prediction models of postmenopausal breast cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Rahman,et al.  Update on the Manchester Scoring System for BRCA1 and BRCA2 testing , 2005, Journal of Medical Genetics.

[31]  H. Nevanlinna,et al.  A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families , 2001, British Journal of Cancer.

[32]  M. Ennis,et al.  Selecting a BRCA risk assessment model for use in a familial cancer clinic , 2008, BMC Medical Genetics.

[33]  Julie O. Culver,et al.  Limited family structure and BRCA gene mutation status in single cases of breast cancer. , 2007, JAMA.

[34]  Melissa Bondy,et al.  Projecting individualized absolute invasive breast cancer risk in African American women. , 2007, Journal of the National Cancer Institute.

[35]  G A Colditz,et al.  Nurses' health study: log-incidence mathematical model of breast cancer incidence. , 1996, Journal of the National Cancer Institute.

[36]  F. Berrino,et al.  Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability , 2014, Familial Cancer.

[37]  M. Morrow Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial , 2007 .

[38]  S. Narod Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 1999, Journal of the National Cancer Institute.

[39]  M. Rué,et al.  An assessment of existing models for individualized breast cancer risk estimation in a screening program in Spain , 2013, BMC Cancer.

[40]  F. Couch,et al.  BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. , 1997, The New England journal of medicine.

[41]  W. McCaskill-Stevens,et al.  Breast Cancer Risk Assessments Comparing Gail and CARE Models in African‐American Women , 2009, The breast journal.

[42]  Karla Kerlikowske,et al.  The contributions of breast density and common genetic variation to breast cancer risk. , 2015, Journal of the National Cancer Institute.

[43]  M. Gail,et al.  Is the Benign Breast Disease Breast Cancer Model Well Calibrated? , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  R. Eeles,et al.  Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics , 2008, Journal of Medical Genetics.

[45]  D. Amadori,et al.  Intake of macronutrients and risk of breast cancer , 1996, The Lancet.

[46]  Karla Kerlikowske,et al.  Using Clinical Factors and Mammographic Breast Density to Estimate Breast Cancer Risk: Development and Validation of a New Predictive Model , 2008, Annals of Internal Medicine.

[47]  A. Leitch,et al.  Limitations of the Gail Model in the Specialized Breast Cancer Risk Assessment Clinic , 2002, The breast journal.

[48]  D. Palli,et al.  The Florence City Sample: Dietary and Life-Style Habits of a Representative Sample of Adult Residents. A Comparison with the Epic-Florence Volunteers , 2003, Tumori.

[49]  Ivar Heuch,et al.  Population attributable risk for breast cancer: diet, nutrition, and physical exercise. , 2000 .

[50]  C. la Vecchia,et al.  Population attributable risk for breast cancer: diet, nutrition, and physical exercise. , 1998, Journal of the National Cancer Institute.

[51]  Jinbo Chen,et al.  Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. , 2006, Journal of the National Cancer Institute.

[52]  U. P. S. T. Force Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement , 2005, Annals of Internal Medicine.

[53]  Karla Kerlikowske,et al.  Benign breast disease, mammographic breast density, and the risk of breast cancer. , 2013, Journal of the National Cancer Institute.

[54]  Susan M. Domchek,et al.  Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study , 2010, Familial Cancer.

[55]  JoAnn E. Manson,et al.  Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. , 1998, Controlled clinical trials.

[56]  D. Berry,et al.  Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. , 1997, Journal of the National Cancer Institute.

[57]  J. Cuzick,et al.  Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  A Howell,et al.  Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme , 2003, Journal of medical genetics.

[59]  D. Easton,et al.  The BOADICEA model of genetic susceptibility to breast and ovarian cancer , 2004, British Journal of Cancer.

[60]  N. Risch,et al.  The calculation of breast cancer risk for women with a first degree family history of ovarian cancer , 1993, Breast Cancer Research and Treatment.

[61]  Mitchell H Gail,et al.  Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women , 2017, Journal of the National Cancer Institute.

[62]  S. Cummings,et al.  Mammographic Breast Density and the Gail Model for Breast Cancer Risk Prediction in a Screening Population , 2005, Breast Cancer Research and Treatment.

[63]  J. Kirk,et al.  Evaluation of models to predict BRCA germline mutations , 2006, British Journal of Cancer.

[64]  J. Lee,et al.  Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients , 2012, Breast Cancer Research and Treatment.

[65]  V Shane Pankratz,et al.  Model for individualized prediction of breast cancer risk after a benign breast biopsy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  Stephen W Duffy,et al.  A breast cancer prediction model incorporating familial and personal risk factors , 2004, Hereditary Cancer in Clinical Practice.

[67]  Z. Miedzybrodzka,et al.  Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models , 2007, Familial Cancer.

[68]  M. Yaffe,et al.  American Cancer Society Guidelines for Breast Screening with MRI as an Adjunct to Mammography , 2007 .

[69]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[70]  Karla Kerlikowske,et al.  Prospective breast cancer risk prediction model for women undergoing screening mammography. , 2006, Journal of the National Cancer Institute.

[71]  Konstantin Strauch,et al.  Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance , 2012, Breast Cancer Research.

[72]  C A Bodian,et al.  Lobular neoplasia: Long term risk of breast cancer and relation to other factors , 1996, Cancer.

[73]  U. P. S. T. Force,et al.  Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer: US Preventive Services Task Force Recommendation Statement , 2019, Obstetrical & Gynecological Survey.

[74]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[75]  C. Specchia,et al.  Epic-Italy Cohorts and Multipurpose National Surveys. A Comparison of Some Socio-Demographic and Life-Style Characteristics , 2003, Tumori.

[76]  Jacques Simard,et al.  Incorporating Truncating Variants in PALB2, CHEK2 and ATM into the BOADICEA Breast Cancer Risk Model , 2016, Genetics in Medicine.

[77]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[78]  E. Halpern,et al.  Mammographic breast density and race. , 2007, AJR. American journal of roentgenology.

[79]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[80]  N. Rahman,et al.  A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO , 2004, Journal of Medical Genetics.

[81]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[82]  M. Bani,et al.  Evaluation of mathematical models for breast cancer risk assessment in routine clinical use , 2007, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[83]  G. Colditz,et al.  Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. , 2000, American journal of epidemiology.

[84]  J Benichou,et al.  Validation studies for models projecting the risk of invasive and total breast cancer incidence. , 1999, Journal of the National Cancer Institute.

[85]  D. Noh,et al.  Validation of Risk Assessment Models for Predicting the Incidence of Breast Cancer in Korean Women , 2014, Journal of breast cancer.

[86]  V Shane Pankratz,et al.  Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  Alan D. Lopez,et al.  Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study , 2017, JAMA oncology.

[88]  Validity of Models for Predicting BRCA1 and BRCA2 Mutations , 2007, Annals of Internal Medicine.

[89]  S. Cummings,et al.  Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  E A Jones,et al.  Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing , 2009, Journal of Medical Genetics.

[91]  Spratt Js,et al.  Assessing the risk of breast cancer. , 2000 .

[92]  Susan M. Astley,et al.  Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort , 2015, Breast Cancer Research.

[93]  E. Schröck,et al.  Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium , 2013, Journal of Medical Genetics.

[94]  A. Meindl,et al.  Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer , 2014, International journal of cancer.

[95]  Stephen W Duffy,et al.  Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I , 2014, Breast Cancer Research.

[96]  Sean V Tavtigian,et al.  Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[97]  D Spiegelman,et al.  Validation of the Gail et al. model for predicting individual breast cancer risk. , 1994, Journal of the National Cancer Institute.

[98]  G. Mills,et al.  Assessing BRCA carrier probabilities in extended families. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  Giovanni Parmigiani,et al.  Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO , 2015, Cancer informatics.

[100]  D. Evans,et al.  Assessing women at high risk of breast cancer: a review of risk assessment models. , 2010, Journal of the National Cancer Institute.

[101]  D. Bowen,et al.  Comparisons of two breast cancer risk estimates in women with a family history of breast cancer. , 2001, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[102]  D. English,et al.  Associations of mammographic dense and nondense areas and body mass index with risk of breast cancer. , 2014, American journal of epidemiology.

[103]  N Risch,et al.  Autosomal dominant inheritance of early‐onset breast cancer. Implications for risk prediction , 1994, Cancer.

[104]  Elpiniki I. Papageorgiou,et al.  An integrated breast cancer risk assessment and management model based on fuzzy cognitive maps , 2015, Comput. Methods Programs Biomed..

[105]  C. Jacobi,et al.  Risk Estimation for Healthy Women from Breast Cancer Families , 2004, Cancer Epidemiology Biomarkers & Prevention.

[106]  Alan B Hollingsworth,et al.  An Alternative Approach to Selecting Patients for High‐risk Screening with Breast MRI , 2014, The breast journal.

[107]  Thea D. Tlsty,et al.  Benign breast disease and the risk of breast cancer. , 2005 .

[108]  S. Singletary Rating the Risk Factors for Breast Cancer , 2003, Annals of surgery.